Biliary Tract Cancer Clinical Trials in Beijing, Beijing Municipality
9 recruitingBeijing, Beijing Municipality, China
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Biliary Tract CancerMelanoma
Hangzhou Hanx Biopharmaceuticals, Ltd.124 enrolled1 locationNCT06708663
Recruiting
Phase 1Phase 2
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.102 enrolled43 locationsNCT06431490
Recruiting
Phase 2
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.151 enrolled2 locationsNCT07450976
Recruiting
Phase 3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Biliary Tract Cancer
Jazz Pharmaceuticals286 enrolled184 locationsNCT06282575
Recruiting
Phase 1
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Gastric CancerEsophageal AdenocarcinomaMetastatic Cancer+5 more
I-Mab Biopharma US Limited330 enrolled21 locationsNCT04900818
Recruiting
Phase 1Phase 2
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Biliary Tract Cancer
Akeso135 enrolled1 locationNCT06938321
Recruiting
Phase 2
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
Biliary Tract Cancer
Peking Union Medical College Hospital45 enrolled1 locationNCT07267078
Recruiting
Phase 2
Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer
Biliary Tract Cancer (BTC)
Peking Union Medical College Hospital100 enrolled1 locationNCT07159204
Recruiting
Phase 2
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
Advanced Biliary Tract Cancer
Dai, Guanghai35 enrolled1 locationNCT06708858